Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01296113 | Chemotherapy for Lung Cancer in HIV-positive Patients(CHIVA) | completed | Phase 2 | 61 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03825510 | Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect(I-SABR) | completed | Phase 2 | 3 | Crozer-Keystone Health SystemOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03904563 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT02151604 | Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy | completed | Phase 2 | 22 | Oxford University Hospitals NHS TrustOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT03693547 | Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | completed | Phase 2 | 26 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00312728 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | completed | Phase 2 | 115 | Genentech, Inc.INDUSTRY | 0 | Jan 6, 2023 | clinicaltrials |
| NCT02591615 | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | completed | Phase 2 | 91 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04201756 | Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma | completed | Phase 2 | 47 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03853187 | Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer(Donan) | completed | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03090737 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer(CheckMate 907) | completed | Phase 2 | 129 | Bristol-Myers SquibbINDUSTRY | 5 | Dec 5, 2022 | clinicaltrials |
| NCT03360929 | Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 | completed | Phase 1 / Phase 2 | 15 | LYZZ Alpha Holding LtdINDUSTRY | 1 | Nov 25, 2022 | clinicaltrials |
| NCT01649947 | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | completed | Phase 2 | 32 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | completed | Phase 1 / Phase 2 | 267 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03900117 | Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC | completed | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT02448225 | 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules | completed | Phase 2 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02898116 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | completed | Phase 1 / Phase 2 | 61 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT00054314 | BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | — | Roswell Park Cancer InstituteOTHER | 0 | Sep 26, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | completed | Phase 1 / Phase 2 | 141 | Syndax PharmaceuticalsINDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT00970684 | Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 13 | Nathan Pennell, MD, PhDOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT02716311 | Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer(ACE-Lung) | completed | Phase 2 | 118 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02328105 | LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT00553800 | Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03623750 | E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C(EPICAL) | completed | Phase 1 / Phase 2 | 23 | Instituto Oncológico Dr RosellOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04507906 | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | completed | Phase 1 / Phase 2 | 21 | Shanghai Chest HospitalOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT00097851 | Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 100 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00103389 | Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 98 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT02920476 | TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | completed | Phase 2 | 4 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT00376623 | Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 96 | Boehringer IngelheimINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02183870 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer(EUCROSS) | completed | Phase 2 | 34 | University of CologneOTHER | 3 | Jun 16, 2022 | clinicaltrials |
| NCT00979212 | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | completed | Phase 2 | 71 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 40 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT00750269 | Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 120 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | completed | Phase 2 | 43 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Jun 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 23, 2023source: clinicaltrials